Anebulo Historical Financial Ratios

ANEB Stock

USD 1.36 0.04 2.86%

Anebulo Pharmaceuticals is presently reporting on over 76 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 17.15 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Anebulo Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anebulo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.

About Anebulo Financial Ratios Analysis

Anebulo PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Anebulo Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Anebulo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Anebulo Pharmaceuticals history.

Anebulo Pharmaceuticals Financial Ratios Chart

At present, Anebulo Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 17.15, whereas Book Value Per Share is forecasted to decline to 0.16.

Average Payables Cash Per Share Income Quality Current Ratio

Add Fundamental

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Income Quality

An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.

Current Ratio

A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.

Most ratios from Anebulo Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Anebulo Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anebulo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.At present, Anebulo Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 17.15, whereas Book Value Per Share is forecasted to decline to 0.16.

Anebulo Pharmaceuticals fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Pb Ratio	Free Cash Flow Per Share	Roic	Net Income Per Share	Average Inventory	Cash Per Share	Pocfratio	Interest Coverage	Pfcf Ratio	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Net Debt To E B I T D A	Current Ratio	Tangible Book Value Per Share	Shareholders Equity Per Share	Debt To Equity
Ptb Ratio		0.75	-0.86	-0.96	-0.51	1.0	-0.96	-0.77	-0.72	0.47	0.58	1.0	-0.92	1.0	-0.41	-0.95	1.0	1.0	-0.87	1.0	-0.92	-0.34	0.45	0.75	0.75	0.47
Book Value Per Share	0.75		-0.37	-0.57	-0.01	0.75	-0.57	-0.17	-0.91	0.02	0.97	0.75	-0.46	0.75	-0.74	-0.56	0.75	0.75	-0.43	0.75	-0.73	-0.48	0.87	1.0	1.0	0.02
Free Cash Flow Yield	-0.86	-0.37		0.96	0.56	-0.86	0.96	0.9	0.41	-0.58	-0.18	-0.86	0.93	-0.86	0.09	0.89	-0.86	-0.86	0.86	-0.86	0.85	0.03	-0.04	-0.37	-0.37	-0.58
Operating Cash Flow Per Share	-0.96	-0.57	0.96		0.54	-0.96	1.0	0.87	0.58	-0.57	-0.39	-0.96	0.96	-0.96	0.27	0.96	-0.96	-0.96	0.9	-0.96	0.91	0.2	-0.25	-0.57	-0.57	-0.58
Average Payables	-0.51	-0.01	0.56	0.54		-0.51	0.54	0.76	0.14	-0.4	0.18	-0.51	0.59	-0.51	-0.25	0.66	-0.51	-0.51	0.71	-0.51	0.4	-0.1	0.12	-0.01	-0.01	-0.39
Pb Ratio	1.0	0.75	-0.86	-0.96	-0.51		-0.96	-0.77	-0.72	0.47	0.58	1.0	-0.92	1.0	-0.41	-0.95	1.0	1.0	-0.87	1.0	-0.92	-0.34	0.45	0.75	0.75	0.47
Free Cash Flow Per Share	-0.96	-0.57	0.96	1.0	0.54	-0.96		0.87	0.58	-0.57	-0.39	-0.96	0.96	-0.96	0.27	0.96	-0.96	-0.96	0.9	-0.96	0.91	0.2	-0.25	-0.57	-0.57	-0.58
Roic	-0.77	-0.17	0.9	0.87	0.76	-0.77	0.87		0.26	-0.76	0.06	-0.77	0.89	-0.77	-0.01	0.91	-0.77	-0.76	0.94	-0.77	0.69	-0.03	0.09	-0.17	-0.17	-0.76
Net Income Per Share	-0.72	-0.91	0.41	0.58	0.14	-0.72	0.58	0.26		-0.12	-0.85	-0.72	0.39	-0.72	0.85	0.64	-0.72	-0.73	0.57	-0.72	0.82	0.09	-0.92	-0.91	-0.91	-0.12
Average Inventory	0.47	0.02	-0.58	-0.57	-0.4	0.47	-0.57	-0.76	-0.12		-0.15	0.47	-0.6	0.47	-0.05	-0.64	0.47	0.47	-0.71	0.47	-0.43	0.09	-0.09	0.02	0.02	1.0
Cash Per Share	0.58	0.97	-0.18	-0.39	0.18	0.58	-0.39	0.06	-0.85	-0.15		0.58	-0.27	0.58	-0.74	-0.35	0.58	0.59	-0.21	0.58	-0.59	-0.49	0.89	0.97	0.97	-0.15
Pocfratio	1.0	0.75	-0.86	-0.96	-0.51	1.0	-0.96	-0.77	-0.72	0.47	0.58		-0.92	1.0	-0.41	-0.95	1.0	1.0	-0.87	1.0	-0.92	-0.34	0.45	0.75	0.75	0.47
Interest Coverage	-0.92	-0.46	0.93	0.96	0.59	-0.92	0.96	0.89	0.39	-0.6	-0.27	-0.92		-0.92	0.07	0.9	-0.92	-0.91	0.84	-0.92	0.77	0.36	-0.06	-0.46	-0.46	-0.6
Pfcf Ratio	1.0	0.75	-0.86	-0.96	-0.51	1.0	-0.96	-0.77	-0.72	0.47	0.58	1.0	-0.92		-0.41	-0.95	1.0	1.0	-0.87	1.0	-0.92	-0.34	0.45	0.75	0.75	0.47
Income Quality	-0.41	-0.74	0.09	0.27	-0.25	-0.41	0.27	-0.01	0.85	-0.05	-0.74	-0.41	0.07	-0.41		0.35	-0.41	-0.41	0.32	-0.41	0.54	0.02	-0.9	-0.74	-0.74	-0.05
Roe	-0.95	-0.56	0.89	0.96	0.66	-0.95	0.96	0.91	0.64	-0.64	-0.35	-0.95	0.9	-0.95	0.35		-0.95	-0.95	0.98	-0.95	0.9	0.1	-0.33	-0.56	-0.56	-0.65
Ev To Operating Cash Flow	1.0	0.75	-0.86	-0.96	-0.51	1.0	-0.96	-0.77	-0.72	0.47	0.58	1.0	-0.92	1.0	-0.41	-0.95		1.0	-0.87	1.0	-0.92	-0.34	0.45	0.75	0.75	0.47
Pe Ratio	1.0	0.75	-0.86	-0.96	-0.51	1.0	-0.96	-0.76	-0.73	0.47	0.59	1.0	-0.91	1.0	-0.41	-0.95	1.0		-0.87	1.0	-0.92	-0.34	0.46	0.75	0.75	0.47
Return On Tangible Assets	-0.87	-0.43	0.86	0.9	0.71	-0.87	0.9	0.94	0.57	-0.71	-0.21	-0.87	0.84	-0.87	0.32	0.98	-0.87	-0.87		-0.87	0.84	-0.05	-0.26	-0.43	-0.43	-0.71
Ev To Free Cash Flow	1.0	0.75	-0.86	-0.96	-0.51	1.0	-0.96	-0.77	-0.72	0.47	0.58	1.0	-0.92	1.0	-0.41	-0.95	1.0	1.0	-0.87		-0.92	-0.34	0.45	0.75	0.75	0.47
Earnings Yield	-0.92	-0.73	0.85	0.91	0.4	-0.92	0.91	0.69	0.82	-0.43	-0.59	-0.92	0.77	-0.92	0.54	0.9	-0.92	-0.92	0.84	-0.92		0.02	-0.55	-0.73	-0.73	-0.43
Net Debt To E B I T D A	-0.34	-0.48	0.03	0.2	-0.1	-0.34	0.2	-0.03	0.09	0.09	-0.49	-0.34	0.36	-0.34	0.02	0.1	-0.34	-0.34	-0.05	-0.34	0.02		-0.14	-0.48	-0.48	0.09
Current Ratio	0.45	0.87	-0.04	-0.25	0.12	0.45	-0.25	0.09	-0.92	-0.09	0.89	0.45	-0.06	0.45	-0.9	-0.33	0.45	0.46	-0.26	0.45	-0.55	-0.14		0.87	0.87	-0.09
Tangible Book Value Per Share	0.75	1.0	-0.37	-0.57	-0.01	0.75	-0.57	-0.17	-0.91	0.02	0.97	0.75	-0.46	0.75	-0.74	-0.56	0.75	0.75	-0.43	0.75	-0.73	-0.48	0.87		1.0	0.02
Shareholders Equity Per Share	0.75	1.0	-0.37	-0.57	-0.01	0.75	-0.57	-0.17	-0.91	0.02	0.97	0.75	-0.46	0.75	-0.74	-0.56	0.75	0.75	-0.43	0.75	-0.73	-0.48	0.87	1.0		0.02
Debt To Equity	0.47	0.02	-0.58	-0.58	-0.39	0.47	-0.58	-0.76	-0.12	1.0	-0.15	0.47	-0.6	0.47	-0.05	-0.65	0.47	0.47	-0.71	0.47	-0.43	0.09	-0.09	0.02	0.02

Click cells to compare fundamentals

Anebulo Pharmaceuticals Account Relationship Matchups

Anebulo Pharmaceuticals fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	7.44	8.06	5.56	18.15	16.34	17.15
Book Value Per Share	0.92	0.65	0.42	0.15	0.17	0.16
Free Cash Flow Yield	(0.0306)	(0.0448)	(0.16)	(0.12)	(0.13)	(0.14)
Operating Cash Flow Per Share	(0.21)	(0.23)	(0.39)	(0.31)	(0.36)	(0.38)
Pb Ratio	7.44	8.06	5.56	18.15	16.34	17.15
Free Cash Flow Per Share	(0.21)	(0.23)	(0.39)	(0.31)	(0.36)	(0.38)
Roic	(0.17)	(0.45)	(1.09)	(2.18)	(2.51)	(2.38)
Pocfratio	(32.68)	(22.33)	(6.09)	(8.55)	(7.7)	(8.08)
Pfcf Ratio	(32.68)	(22.33)	(6.09)	(8.55)	(7.7)	(8.08)
Income Quality	0.16	0.8	0.83	0.99	0.89	0.58
Roe	(1.41)	(0.45)	(1.11)	(2.15)	(2.47)	(2.35)
Ev To Operating Cash Flow	(28.58)	(19.65)	(4.92)	(8.17)	(7.35)	(7.72)
Pe Ratio	(5.26)	(17.82)	(5.02)	(8.44)	(7.59)	(7.97)
Return On Tangible Assets	(1.4)	(0.44)	(1.01)	(2.01)	(2.32)	(2.2)
Ev To Free Cash Flow	(28.58)	(19.65)	(4.92)	(8.17)	(7.35)	(7.72)
Net Debt To E B I T D A	0.66	(2.6K)	0.95	0.38	0.44	0.46
Current Ratio	82.71	28.39	21.04	13.46	15.48	14.71
Tangible Book Value Per Share	0.92	0.65	0.42	0.15	0.17	0.16
Shareholders Equity Per Share	0.92	0.65	0.42	0.15	0.17	0.16
Graham Net Net	0.85	0.6	0.41	0.11	0.13	0.12
Enterprise Value Over E B I T D A	(4.6)	19.2K	(4.05)	(8.21)	(7.39)	(7.02)
Price Earnings Ratio	(5.26)	(17.82)	(5.02)	(8.44)	(7.59)	(7.97)
Price Book Value Ratio	7.44	8.06	5.56	18.15	16.34	17.15
Price To Operating Cash Flows Ratio	(32.68)	(22.33)	(6.09)	(8.55)	(7.7)	(8.08)
Price To Free Cash Flows Ratio	(32.68)	(22.33)	(6.09)	(8.55)	(7.7)	(8.08)
Return On Capital Employed	(0.17)	(0.45)	(1.06)	(2.18)	(2.51)	(2.38)
Quick Ratio	82.71	28.39	21.04	13.46	15.48	14.71
Cash Ratio	82.71	28.39	21.04	11.87	13.66	12.97
Price To Book Ratio	7.44	8.06	5.56	18.15	16.34	17.15
Price Cash Flow Ratio	(32.68)	(22.33)	(6.09)	(8.55)	(7.7)	(8.08)
Enterprise Value Multiple	(4.6)	19.2K	(4.05)	(8.21)	(7.39)	(7.02)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:

How To Invest In Anebulo

Details

Is Anebulo Stock a good investment?

Details

What is Anebulo Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.32)

Return On Assets

(0.66)

Return On Equity

(1.14)

The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Anebulo Historical Financial Ratios

About Anebulo Financial Ratios Analysis

Anebulo Pharmaceuticals Financial Ratios Chart

Average Payables

Income Quality

Current Ratio

Anebulo Pharmaceuticals fundamentals Correlations

Anebulo Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Anebulo Pharmaceuticals fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Pocfratio	+ 1.0	Ptb Ratio
Pfcf Ratio	+ 1.0	Ptb Ratio
Ev To Operating Cash Flow	+ 1.0	Ptb Ratio
Pe Ratio	+ 1.0	Ptb Ratio
Ev To Free Cash Flow	+ 1.0	Ptb Ratio

Ev To Free Cash Flow	- 0.96	Free Cash Flow Per Share
Pe Ratio	- 0.96	Free Cash Flow Per Share
Ev To Operating Cash Flow	- 0.96	Free Cash Flow Per Share
Pfcf Ratio	- 0.96	Free Cash Flow Per Share
Pocfratio	- 0.96	Free Cash Flow Per Share
Free Cash Flow Per Share	- 0.96	Pb Ratio